Sunho Biologics, Inc.
盛禾生物控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2898)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE APPOINTMENT OF INVESTIGATOR AND CONTINUED SUSPENSION OF TRADING

Reference is made to the announcement of Sunho Biologics, Inc. ("**Company**", together with its subsidiaries, the "**Group**") dated June 17, 2026 in relation to the appointment of Investigator ("**Announcement**"). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Company would like to provide the following supplementary information in relation to the appointment of Investigator.

INDEPENDENT INVESTIGATION COMMITTEE'S ASSESSMENT ON THE INVESTIGATOR

In addition to the information disclosed in the Announcement, the Company would like to supplement the following information in relation to the factors considered by the Independent Investigation Committee in respect of the appointment of the Investigator:

1. *Independence:* the Investigator is an independent third party not connected with any of the substantial Shareholders, Directors, or the Company's outgoing or incoming auditors. The Investigator has confirmed that it does not act for the Company, its connected persons (as defined under the Listing Rules), or any persons or entities involved in, or aware of, the irregularities, and has not been involved in any transactions or arrangements relating to the irregularities. The Investigator has further confirmed that it is independent from and not connected with the Company, its subsidiaries, Directors, chief executive, substantial Shareholder(s) or any other connected person (as defined under the Listing Rules) and does not have any direct or indirect shareholding interest in the Company or any member company of the Group.

The Investigator has also confirmed that it does not have any prior or existing business relationship with the Group that would reasonably be considered to impair its independence in conducting the Independent Investigation;

2. *Credentials and qualifications:* the Investigator has deployed an 8-person dedicated forensic team, led by a senior partner with over 18 years of audit and forensic experience, to undertake the Independent Investigation. All engagement team members possess extensive experience in complex financial investigations in both Hong Kong and Mainland China:

   (i) the senior partner designated by the Investigator as the project manager to undertake the engagement has over 18 years of professional experience in audit and forensic services. He is a Fellow of the Hong Kong Institute of Certified Public Accountants (HKICPA), the Institute of Chartered Accountants in England and Wales (ICAEW), and The Taxation Institute of Hong Kong (TIHK), as well as a member of CPA Australia. He is a registered Public Interest Entity (PIE) Auditor with the Accounting and Financial Reporting Council (AFRC);

   (ii) credentials and qualifications of other core team members designated by the Investigator, in addition to the senior partner as mentioned above, are as follows:

      (a) a principal partner with approximately 20 years of experience in audit, compliance, and forensic accounting. He is a member of the HKICPA, a fellow of the ACCA, and an associate of the Hong Kong Chartered Governance Institute (HKCGI). He has extensive forensic experience and has previously acted as an expert witness providing forensic and legal support in the Hong Kong High Court;

      (b) a computer forensic expert with over 20 years of IT experience with specialized expertise in IT auditing, cybersecurity, and digital transformation. He holds international certifications, including GIAC Penetration Tester (GPEN) and ISO 27001, and an MBA degree;

      (c) a senior engineer and nationally certified electronic data forensics expert. He is a council member of the Hong Kong Information Security and Forensics Society (ISFS) and the liaison officer for Greater China. He has been engaged in electronic data forensics practice since 1991. He is also the founder of the CCFC Computer Forensics Conference and he established the CDF Electronic Data Forensics Training Camp in 2015; and

      (d) two forensic advisors both possess over 20 years of experience in internal control, risk management and independent investigations.

3. *Experience:* the engagement team of the Investigator has an extensive track record of successfully undertaking independent forensic investigations for companies listed on the Stock Exchange; and

4. *Resources:* the Investigator has deployed an 8-person dedicated forensic team to undertake the Independent Investigation, and further committed to a pragmatic timetable which aligns with the Company's timetable for fulfilment of the Resumption Guidance. See "Credentials and qualifications" above for details of credentials and qualifications of the key members of the engagement team. The Independent Investigation Committee believed that the team, which combines seasoned financial auditors, internal control specialists and certified digital forensic experts, possesses the appropriate cross-disciplinary expertise required to address the Resumption Guidance.

Based on the above, the Independent Investigation Committee concluded that the Investigator is independent and possesses the credentials, qualifications, experience and resources to conduct the Investigation.

CONTINUED SUSPENSION OF TRADING

Trading in the Shares on the Stock Exchange has been suspended with effect from 9:00 a.m. on April 1, 2026 and will continue to be suspended pending the publication of the 2025 Annual Results by the Company.

Shareholders and potential investors of the Company are advised to exercise due caution when dealing in the securities of the Company. When in doubt, Shareholders and potential investors of the Company are advised to seek advice from professional or financial advisers.

By order of the Board
Sunho Biologics, Inc.
Mr. ZHANG Feng
Chairman and executive Director

Hong Kong, August 19, 2026

As at the date of this announcement, the executive Directors are Mr. ZHANG Feng and Ms. JIANG Xiaoling; and the independent non-executive Directors are Mr. CHAN Heung Wing Anthony, Ms. FENG Lan and Mr. SHI Luwen.